본문 바로가기
KERD
논문KCI 등재

치매 환자에서의 자율신경기능 이상

Autonomic Dysfunction in Patients With Dementia

장성만|이지민
대한노인정신의학회 (Korean Association For Geriatric Psychiatry)|2021.10|노인정신의학 (Journal of Korean Geriatric Psychiatry)|제25권 제2호|pp. 57-64

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

치매Dementia자율신경계Autonomic nervous systemLower urinary tract symptoms기립성 저혈압Orthostatic hypotension하부 요로 증상루이소체병.Lewy body disease

초록

Autonomic dysfunction commonly occurs in patients with dementia and is typically reported in patients with Alzheimer’s disease and Lewy body dementia. The clinical presentation of autonomic dysfunction includes symptoms related to orthostatic hypotension (manifested as dizziness, falls, and syncope, etc.), constipation, and urinary tract symptoms. Non-pharmacological management of orthostatic hypotension should include bolus water drinking. Pharmacological management includes the administration of midodrine (selective α1-adrenoceptor agonist), droxidopa (norepinephrine prodrug), or atomoxetine (selective noradrenaline reuptake inhibitor). Management of constipation includes the administration of probiotics, osmotic laxatives (e.g. macrogol), and type-2 chloride channel activators (e.g. lubiprostone), and management of urinary tract symptoms includes the administration of mirabegron (selective β3-adrenergic receptor). Autonomic dysfunction interferes with daily activities and negatively affects patients’ and caregivers’ quality of life. Therefore, early diagnosis of autonomic dysfunction and prompt initiation of optimal treatment are important to improve patients’ quality of life and prognosis

Abstract

Autonomic dysfunction commonly occurs in patients with dementia and is typically reported in patients with Alzheimer’s disease and Lewy body dementia. The clinical presentation of autonomic dysfunction includes symptoms related to orthostatic hypotension (manifested as dizziness, falls, and syncope, etc.), constipation, and urinary tract symptoms. Non-pharmacological management of orthostatic hypotension should include bolus water drinking. Pharmacological management includes the administration of midodrine (selective α1-adrenoceptor agonist), droxidopa (norepinephrine prodrug), or atomoxetine (selective noradrenaline reuptake inhibitor). Management of constipation includes the administration of probiotics, osmotic laxatives (e.g. macrogol), and type-2 chloride channel activators (e.g. lubiprostone), and management of urinary tract symptoms includes the administration of mirabegron (selective β3-adrenergic receptor). Autonomic dysfunction interferes with daily activities and negatively affects patients’ and caregivers’ quality of life. Therefore, early diagnosis of autonomic dysfunction and prompt initiation of optimal treatment are important to improve patients’ quality of life and prognosis

참고문헌 (62)

  1. Chu CC, "The autonomicrelated cortex : pathology in Alzheimer’s disease", Cereb Cortex, 7, pp.86~95 (1997)
  2. Palma JA, "Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies", Mov Disord, 33, pp.372~390 (2018)
  3. Perry EK, "Cholinergic and dopaminergic activities in senile dementia of Lewy body type", Alzheimer Dis Assoc Disord, 4, pp.87~95 (1990)
  4. Allan L, "The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life", Dement Geriatr Cogn Disord, 22, pp.230~237 (2006)
  5. Allan LM, "Incidence and prediction of falls in dementia: a prospective study in older people", PLoS One, 4, pp.e5521~ (2009)
  6. McDonald C, "Orthostatic hypotension and cognitive impairment in Parkinson’s disease: causation or association?", Mov Disord, 31, pp.937~946 (2016)
  7. Fanciulli A, "The potential prognostic role of cardiovascular autonomic failure in α-synucleinopathies", Eur J Neurol, 20, pp.231~235 (2013)
  8. Elmståhl S, "Autonomic cardiovascular responses to tilting in patients with Alzheimer’s disease and in healthy elderly women", Age Ageing, 21, pp.301~307 (1992)
  9. Vitiello B, "Autonomic dysfunction in patients with dementia of the Alzheimer type", Biol Psychiatry, 34, pp.428~433 (1993)
  10. Wang SJ, "Cardiovascular autonomic functions in Alzheimer’s disease", Age Ageing, 23, pp.400~404 (1994)
  11. Algotsson A, "Autonomic dysfunction in Alzheimer’s disease", Acta Neurol Scand, 91, pp.14~18 (1995)
  12. Idiaquez J, "Association between neuropsychiatric and autonomic dysfunction in Alzheimer’s disease", Clin Auton Res, 12, pp.43~46 (2002)
  13. Allan LM, "Autonomic dysfunction in dementia", J Neurol Neurosurg Psychiatry, 78, pp.671~677 (2007)
  14. Allan LM, "Autonomic function assessed by heart rate variability is normal in Alzheimer’s disease and vascular dementia", Dement Geriatr Cogn Disord, 19, pp.140~144 (2005)
  15. da Silva VP, "Heart rate variability indexes in dementia : a systematic review with a quantitative analysis", Curr Alzheimer Res, 15, pp.80~88 (2018)
  16. Yamamoto T, "Autonomic nervous functions in Alzheimer type and multi-infarct dementia--a hemodynamic study", Rinsho Shinkeigaku, 30, pp.1020~1022 (1990)
  17. Niimi Y, "Baroreflex function in patients with Binswanger’s encephalopathy", Rinsho Shinkeigaku, 39, pp.700~704 (1999)
  18. Kasanuki K, "Impaired heart rate variability in patients with dementia with Lewy bodies : efficacy of electrocardiogram as a supporting diagnostic marker", Parkinsonism Relat Disord, 21, pp.749~754 (2015)
  19. Watanabe H, "Cardiac(123)I-meta-iodobenzylguanidine(MIBG)uptake in dementia with Lewy bodies : comparison with Alzheimer’s disease", J Neurol Neurosurg Psychiatry, 70, pp.781~783 (2001)
  20. MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies, "J Neurol Neurosurg Psychiatry", 2001, 583~588
  21. Kashihara K, "Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies", J Nucl Med, 47, pp.1099~1101 (2006)
  22. Passant U, "Orthostatic hypotension and low blood pressure in organic dementia : a study of prevalence and related clinical characteristics", Int J Geriatr Psychiatry, 12, pp.395~403 (1997)
  23. Mehrabian S, "Relationship between orthostatic hypotension and cognitive impairment in the elderly", J Neurol Sci, 299, pp.45~48 (2010)
  24. Sonnesyn H, "High prevalence of orthostatic hypotension in mild dementia", Dement Geriatr Cogn Disord, 28, pp.307~313 (2009)
  25. Bengtsson-Lindberg M, "Lack of orthostatic symptoms in dementia patients with orthostatic hypotension", Clin Auton Res, 25, pp.87~94 (2015)
  26. "Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology", Neurology, 46, pp.873~880 (1996)
  27. Ewing DJ, "The value of cardiovascular autonomic function tests : 10 years experience in diabetes", Diabetes Care, 8, pp.491~498 (1985)
  28. Low PA, "Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure", Mayo Clin Proc, 68, pp.748~752 (1993)
  29. Freeman R, "Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome", Clin Auton Res, 21, pp.69~72 (2011)
  30. Frith J, "Diagnosing orthostatic hypotension : a narrative review of the evidence", Br Med Bull, 115, pp.123~134 (2015)
  31. McKeith IG, "Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB Consortium", Neurology, 89, pp.88~100 (2017)
  32. Testa G, "Hypotensive drugs and syncope due to orthostatic hypotension in older adults with dementia(syncope and dementia study)", J Am Geriatr Soc, 66, pp.1532~1537 (2018)
  33. Frith J, "New horizons in orthostatic hypotension", Age Ageing, 46, pp.168~174 (2017)
  34. Moonen JE, "Effect of discontinuation of antihypertensive medication on orthostatic hypotension in older persons with mild cognitive impairment : the DANTE Study Leiden", Age Ageing, 45, pp.249~255 (2016)
  35. Wright JT, Jr., "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
  36. Low PA, "Management of neurogenic orthostatic hypotension : an update", Lancet Neurol, 7, pp.451~458 (2008)
  37. Logan IC, "Efficacy of treatments for orthostatic hypotension : a systematic review", Age Ageing, 41, pp.587~594 (2012)
  38. Mills PB, "Nonpharmacologic management of orthostatic hypotension : a systematic review", Arch Phys Med Rehabil, 96, pp.366~375.e366 (2015)
  39. Robinson LJ, "Acceptability of non-drug therapies in older people with orthostatic hypotension : a qualitative study", BMC Geriatr, 18, pp.315~ (2018)
  40. Newton JL, "The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging", Neurology, 91, pp.e652~e656 (2018)
  41. Parsaik AK, "Midodrine for orthostatic hypotension : a systematic review and meta-analysis of clinical trials", J Gen Intern Med, 28, pp.1496~1503 (2013)
  42. Strassheim V, "Droxidopa for orthostatic hypotension : a systematic review and meta-analysis", J Hypertens, 34, pp.1933~1941 (2016)
  43. Ramirez CE, "Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure", Hypertension, 64, pp.1235~1240 (2014)
  44. Gibbons CH, "The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension", J Neurol, 264, pp.1567~1582 (2017)
  45. Maidment I, "Cholinesterase inhibitors for Parkinson’s disease dementia", Cochrane Database Syst Rev, (1), pp.CD004747~ (2006)
  46. da Costa Dias FL, "Cholinesterase inhibitors modulate autonomic function in patients with Alzheimer’s disease and mixed dementia", Curr Alzheimer Res, 10, pp.476~481 (2013)
  47. McLaren AT, "Cardiovascular effects of donepezil in patients with dementia", Dement Geriatr Cogn Disord, 15, pp.183~188 (2003)
  48. van Hooren MR, "Treatment effects for dysphagia in Parkinson’s disease : a systematic review", Parkinsonism Relat Disord, 20, pp.800~807 (2014)
  49. Logemann JA, "A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson’s disease", J Speech Lang Hear Res, 51, pp.173~183 (2008)
  50. Larsson V, "Effects of carbonated liquid on swallowing dysfunction in dementia with Lewy bodies and Parkinson’s disease dementia", Clin Interv Aging, 12, pp.1215~1222 (2017)
  51. Sampson EL, "Enteral tube feeding for older people with advanced dementia", Cochrane Database Syst Rev, (2), pp.CD007209~ (2009)
  52. Clarke G, "How are treatment decisions made about artificial nutrition for individuals at risk of lacking capacity? A systematic literature review", PLoS One, 8, pp.e61475~ (2013)
  53. Brooke J, "Enteral nutrition in dementia : a systematic review", Nutrients, 7, pp.2456~2468 (2015)
  54. Arcand M, "End-of-life issues in advanced dementia: part 1: goals of care, decision-making process, and family education", Can Fam Physician, 61, pp.330~334 (2015)
  55. Arbouw ME, "Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial", Neurology, 74, pp.1203~1207 (2010)
  56. Fasano A, "Gastrointestinal dysfunction in Parkinson’s disease", Lancet Neurol, 14, pp.625~639 (2015)
  57. Sanger GJ, "Ghrelin and motilin receptors as drug targets for gastrointestinal disorders", Nat Rev Gastroenterol Hepatol, 13, pp.38~48 (2016)
  58. Barichella M, "Probiotics and prebiotic fiber for constipation associated with Parkinson disease : an RCT", Neurology, 87, pp.1274~1280 (2016)
  59. Ashraf W, "Constipation in Parkinson’s disease : objective assessment and response to psyllium", Mov Disord, 12, pp.946~951 (1997)
  60. Zangaglia R, "Macrogol for the treatment of constipation in Parkinson’s disease. a randomized placebo-controlled study", Mov Disord, 22, pp.1239~1244 (2007)
  61. Ondo WG, "Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease", Neurology, 78, pp.1650~1654 (2012)
  62. Taylor JP, "New evidence on the management of Lewy body dementia", Lancet Neurol, 19, pp.157~169 (2020)

관련 논문AI추천

치매에서 심혈관계 자율신경기능 이상김성래, 김소현, 김일곤, 송창석, 윤대현, 지기환, 최성혜, 최윤재, 한임태, 홍창기대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2010 · 제9권 제1호루이소체 치매 1례의 진단 및 임상경과김민정, 이상신대한생물치료정신의학회 · 생물치료정신의학2019 · 제25권 제1호Effects of Atomoxetine for the Treatment of Neurogenic Orthostatic Hypotension in Patients With Alpha-synucleinopathies: A Systematic Review of Randomized Controlled Trials and a Focus-Group Discussion김아련, 정유진, Luis E. Okamoto, Woi-Hyun Hong대한신경과학회 · Journal of Clinical Neurology2023 · 제19권 제2호Relationship between Lower Urinary Tract Dysfunction and Dementia조성태, Na Hae Ri대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2020 · 제19권 제3호Donepezil 복용과 연관된 소변실금구본대, 김혜윤, 정태융대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2007 · 제6권 제2호파킨슨병에서 기립저혈압과 인지 기능의 관계김수영, 손은희, 오응석, 이애영, 이주연대한신경과학회 · 대한신경과학회지2018 · 제36권 제4호

이 간행물의 다른 논문 (10건)

COVID-19 환자에서 나타나는 섬망에 대한 고찰최말례, 김용, 김철웅, 한명일pp. 65-69항정신병 약물 사용 및 치매의 심리행동 증상과 알츠하이머 환자의 인지능력 저하와의 연관성정명훈, 장준호, 홍나래, 홍현주, 전덕인pp. 70-75Association of Sub-Threshold Amyloid Retention With Neuropsychological Performance in Cognitively Normal Older Adults Without the APOE ε4 Allele강동우, 이창욱, 임현국, 엄유현, 나해란, 김낙영, 왕성민, 최지원pp. 76-82Predictors of Change in Behavioral Psychological Symptoms of Dementia in Patients With Alzheimer’s Disease in Korea정재균, 김민숙pp. 83-89한국 노인의 자서전적 기억 기능 연구: Korean Version of Thinking About Life Experiences Scale의 개발과 활용박상미, 이창대, 김태희pp. 90-97
원문 보기